DULOXETINE
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (N06AX) — coverage varies; not interchangeable
- Mirtazapine (Remeron RD): general benefit, Not a benefit
- Trazodone (Desyrel): general benefit, Not a benefit
- Venlafaxine (Effexor XR): general benefit
- Vortioxetine (Trintellix): general benefit
- Bupropion (Wellbutrin XL): limited Use 315, Not a benefit
- Desvenlafaxine (Pristiq): not a benefit
17 more in the class list below
AG-Duloxetine · DIN 02475308 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Duloxetine · DIN 02475308
Manufacturer: Angita Pharma Inc.; listing date 2020-11-30
Health Canada: Marketed since 2018-07-19 · brand AG-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Angita pharma inc. · schedule Prescription
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96567 · Verify on the e-Formulary ↗ (DIN 02475308)
Source record
DIN 02475308: AG-Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id ANG
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.4814; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475308
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96567
Interchangeable products
Accel-Duloxetine · DIN 02522861 · $0.3611
Apo-Duloxetine · DIN 02440423 · $0.3611
Auro-Duloxetine · DIN 02436647 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02453630 · $0.3611
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
Jamp-Duloxetine · DIN 02451913 · $0.3611
M-Duloxetine · DIN 02473208 · $0.3611
Mar-Duloxetine · DIN 02446081 · $0.3611
Mint-Duloxetine · DIN 02438984 · $0.3611
NRA-Duloxetine · DIN 02482126 · $0.3611
PMS-Duloxetine · DIN 02429446 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Sandoz Duloxetine · DIN 02439948 · $0.3611
Taro-Duloxetine · DIN 02457199 · $0.3611
Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02475308
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Accel-Duloxetine · DIN 02522861 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Accel-Duloxetine · DIN 02522861
Manufacturer: Accel Pharma Inc.; listing date 2022-05-31
Health Canada: Marketed since 2022-04-04 · brand ACCEL-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Accel pharma inc · schedule Prescription
Accel-Duloxetine: Formulary list price $0.3611/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101196 · Verify on the e-Formulary ↗ (DIN 02522861)
Source record
DIN 02522861: Accel-Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id ACC
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.3611; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522861
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101196
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611
Apo-Duloxetine · DIN 02440423 · $0.3611
Auro-Duloxetine · DIN 02436647 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02453630 · $0.3611
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
Jamp-Duloxetine · DIN 02451913 · $0.3611
M-Duloxetine · DIN 02473208 · $0.3611
Mar-Duloxetine · DIN 02446081 · $0.3611
Mint-Duloxetine · DIN 02438984 · $0.3611
NRA-Duloxetine · DIN 02482126 · $0.3611
PMS-Duloxetine · DIN 02429446 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Sandoz Duloxetine · DIN 02439948 · $0.3611
Taro-Duloxetine · DIN 02457199 · $0.3611
Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02522861
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Duloxetine · DIN 02440423 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Duloxetine · DIN 02440423
Manufacturer: Apotex Inc.; listing date 2016-06-29
Health Canada: Marketed since 2016-05-03 · brand APO-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Apotex inc · schedule Prescription
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92479 · Verify on the e-Formulary ↗ (DIN 02440423)
Source record
DIN 02440423: Apo-Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id APX
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.4814; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02440423
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92479
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611
Accel-Duloxetine · DIN 02522861 · $0.3611
Auro-Duloxetine · DIN 02436647 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02453630 · $0.3611
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
Jamp-Duloxetine · DIN 02451913 · $0.3611
M-Duloxetine · DIN 02473208 · $0.3611
Mar-Duloxetine · DIN 02446081 · $0.3611
Mint-Duloxetine · DIN 02438984 · $0.3611
NRA-Duloxetine · DIN 02482126 · $0.3611
PMS-Duloxetine · DIN 02429446 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Sandoz Duloxetine · DIN 02439948 · $0.3611
Taro-Duloxetine · DIN 02457199 · $0.3611
Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: active shortage (reported 2026-07-28, estimated to end 2026-11-06, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02440423
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Duloxetine · DIN 02436647 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Duloxetine · DIN 02436647
Manufacturer: Auro Pharma Inc.; listing date 2016-06-29
Health Canada: Marketed since 2016-05-02 · brand AURO-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Auro pharma inc · schedule Prescription
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92097 · Verify on the e-Formulary ↗ (DIN 02436647)
Source record
DIN 02436647: Auro-Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id AUR
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.4814; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02436647
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92097
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611
Accel-Duloxetine · DIN 02522861 · $0.3611
Apo-Duloxetine · DIN 02440423 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02453630 · $0.3611
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
Jamp-Duloxetine · DIN 02451913 · $0.3611
M-Duloxetine · DIN 02473208 · $0.3611
Mar-Duloxetine · DIN 02446081 · $0.3611
Mint-Duloxetine · DIN 02438984 · $0.3611
NRA-Duloxetine · DIN 02482126 · $0.3611
PMS-Duloxetine · DIN 02429446 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Sandoz Duloxetine · DIN 02439948 · $0.3611
Taro-Duloxetine · DIN 02457199 · $0.3611
Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: resolved shortage (ended 2025-02-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02436647
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Duloxetine · DIN 02453630 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Duloxetine · DIN 02453630
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2016-05-05 · brand DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94019 · Verify on the e-Formulary ↗ (DIN 02453630)
Source record
DIN 02453630: Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id SIV
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.4814; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02453630
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94019
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611
Accel-Duloxetine · DIN 02522861 · $0.3611
Apo-Duloxetine · DIN 02440423 · $0.3611
Auro-Duloxetine · DIN 02436647 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
Jamp-Duloxetine · DIN 02451913 · $0.3611
M-Duloxetine · DIN 02473208 · $0.3611
Mar-Duloxetine · DIN 02446081 · $0.3611
Mint-Duloxetine · DIN 02438984 · $0.3611
NRA-Duloxetine · DIN 02482126 · $0.3611
PMS-Duloxetine · DIN 02429446 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Sandoz Duloxetine · DIN 02439948 · $0.3611
Taro-Duloxetine · DIN 02457199 · $0.3611
Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: resolved shortage (ended 2018-08-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453630
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Duloxetine · DIN 02451913 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Duloxetine · DIN 02451913
Manufacturer: Jamp Pharma Corporation; listing date 2016-07-28
Health Canada: Marketed since 2016-05-03 · brand JAMP-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Jamp pharma corporation · schedule Prescription
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93831 · Verify on the e-Formulary ↗ (DIN 02451913)
Source record
DIN 02451913: Jamp-Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id JPC
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.4814; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02451913
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93831
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611
Accel-Duloxetine · DIN 02522861 · $0.3611
Apo-Duloxetine · DIN 02440423 · $0.3611
Auro-Duloxetine · DIN 02436647 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02453630 · $0.3611
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
M-Duloxetine · DIN 02473208 · $0.3611
Mar-Duloxetine · DIN 02446081 · $0.3611
Mint-Duloxetine · DIN 02438984 · $0.3611
NRA-Duloxetine · DIN 02482126 · $0.3611
PMS-Duloxetine · DIN 02429446 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Sandoz Duloxetine · DIN 02439948 · $0.3611
Taro-Duloxetine · DIN 02457199 · $0.3611
Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02451913
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Duloxetine · DIN 02473208 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Duloxetine · DIN 02473208
Manufacturer: Mantra Pharma Inc.; listing date 2021-11-30
Health Canada: Marketed since 2019-06-27 · brand M-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Mantra pharma inc · schedule Prescription
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96254 · Verify on the e-Formulary ↗ (DIN 02473208)
Source record
DIN 02473208: M-Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id MAT
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.4814; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02473208
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96254
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611
Accel-Duloxetine · DIN 02522861 · $0.3611
Apo-Duloxetine · DIN 02440423 · $0.3611
Auro-Duloxetine · DIN 02436647 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02453630 · $0.3611
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
Jamp-Duloxetine · DIN 02451913 · $0.3611
Mar-Duloxetine · DIN 02446081 · $0.3611
Mint-Duloxetine · DIN 02438984 · $0.3611
NRA-Duloxetine · DIN 02482126 · $0.3611
PMS-Duloxetine · DIN 02429446 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Sandoz Duloxetine · DIN 02439948 · $0.3611
Taro-Duloxetine · DIN 02457199 · $0.3611
Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: resolved shortage (ended 2024-05-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02473208
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Duloxetine · DIN 02446081 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Duloxetine · DIN 02446081
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2016-08-30
Health Canada: Marketed since 2019-05-14 · brand MAR-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Marcan pharmaceuticals inc · schedule Prescription
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93136 · Verify on the e-Formulary ↗ (DIN 02446081)
Source record
DIN 02446081: Mar-Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id MAR
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.4814; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02446081
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93136
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611
Accel-Duloxetine · DIN 02522861 · $0.3611
Apo-Duloxetine · DIN 02440423 · $0.3611
Auro-Duloxetine · DIN 02436647 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02453630 · $0.3611
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
Jamp-Duloxetine · DIN 02451913 · $0.3611
M-Duloxetine · DIN 02473208 · $0.3611
Mint-Duloxetine · DIN 02438984 · $0.3611
NRA-Duloxetine · DIN 02482126 · $0.3611
PMS-Duloxetine · DIN 02429446 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Sandoz Duloxetine · DIN 02439948 · $0.3611
Taro-Duloxetine · DIN 02457199 · $0.3611
Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: resolved shortage (ended 2024-03-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02446081
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Duloxetine · DIN 02438984 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Duloxetine · DIN 02438984
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2016-06-29
Health Canada: Marketed since 2016-05-02 · brand MINT-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Mint pharmaceuticals inc · schedule Prescription
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92335 · Verify on the e-Formulary ↗ (DIN 02438984)
Source record
DIN 02438984: Mint-Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id MIN
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.4814; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02438984
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92335
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611
Accel-Duloxetine · DIN 02522861 · $0.3611
Apo-Duloxetine · DIN 02440423 · $0.3611
Auro-Duloxetine · DIN 02436647 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02453630 · $0.3611
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
Jamp-Duloxetine · DIN 02451913 · $0.3611
M-Duloxetine · DIN 02473208 · $0.3611
Mar-Duloxetine · DIN 02446081 · $0.3611
NRA-Duloxetine · DIN 02482126 · $0.3611
PMS-Duloxetine · DIN 02429446 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Sandoz Duloxetine · DIN 02439948 · $0.3611
Taro-Duloxetine · DIN 02457199 · $0.3611
Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: resolved shortage (ended 2024-01-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02438984
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Duloxetine · DIN 02482126 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Duloxetine · DIN 02482126
Manufacturer: Nora Pharma; listing date 2020-07-31
Health Canada: Marketed since 2019-03-06 · brand NRA-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Nora pharma inc · schedule Prescription
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97243 · Verify on the e-Formulary ↗ (DIN 02482126)
Source record
DIN 02482126: NRA-Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id NRA
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.4814; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02482126
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97243
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611
Accel-Duloxetine · DIN 02522861 · $0.3611
Apo-Duloxetine · DIN 02440423 · $0.3611
Auro-Duloxetine · DIN 02436647 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02453630 · $0.3611
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
Jamp-Duloxetine · DIN 02451913 · $0.3611
M-Duloxetine · DIN 02473208 · $0.3611
Mar-Duloxetine · DIN 02446081 · $0.3611
Mint-Duloxetine · DIN 02438984 · $0.3611
PMS-Duloxetine · DIN 02429446 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Sandoz Duloxetine · DIN 02439948 · $0.3611
Taro-Duloxetine · DIN 02457199 · $0.3611
Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02482126
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Duloxetine · DIN 02429446 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Duloxetine · DIN 02429446
Manufacturer: Pharmascience Inc.; listing date 2016-06-29
Health Canada: Marketed since 2016-05-02 · brand PMS-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Pharmascience inc · schedule Prescription
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91389 · Verify on the e-Formulary ↗ (DIN 02429446)
Source record
DIN 02429446: PMS-Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id PMS
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.4814; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429446
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91389
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611
Accel-Duloxetine · DIN 02522861 · $0.3611
Apo-Duloxetine · DIN 02440423 · $0.3611
Auro-Duloxetine · DIN 02436647 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02453630 · $0.3611
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
Jamp-Duloxetine · DIN 02451913 · $0.3611
M-Duloxetine · DIN 02473208 · $0.3611
Mar-Duloxetine · DIN 02446081 · $0.3611
Mint-Duloxetine · DIN 02438984 · $0.3611
NRA-Duloxetine · DIN 02482126 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Sandoz Duloxetine · DIN 02439948 · $0.3611
Taro-Duloxetine · DIN 02457199 · $0.3611
Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: resolved shortage (ended 2019-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02429446
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Duloxetine · DIN 02439948 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Duloxetine · DIN 02439948
Manufacturer: Sandoz Canada Inc.; listing date 2016-06-29
Health Canada: Marketed since 2016-05-02 · brand SANDOZ DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Sandoz canada incorporated · schedule Prescription
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92433 · Verify on the e-Formulary ↗ (DIN 02439948)
Source record
DIN 02439948: Sandoz Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id SDZ
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.4814; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02439948
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92433
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611
Accel-Duloxetine · DIN 02522861 · $0.3611
Apo-Duloxetine · DIN 02440423 · $0.3611
Auro-Duloxetine · DIN 02436647 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02453630 · $0.3611
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
Jamp-Duloxetine · DIN 02451913 · $0.3611
M-Duloxetine · DIN 02473208 · $0.3611
Mar-Duloxetine · DIN 02446081 · $0.3611
Mint-Duloxetine · DIN 02438984 · $0.3611
NRA-Duloxetine · DIN 02482126 · $0.3611
PMS-Duloxetine · DIN 02429446 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Taro-Duloxetine · DIN 02457199 · $0.3611
Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: resolved shortage (ended 2025-09-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02439948
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Duloxetine · DIN 02457199 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Taro-Duloxetine · DIN 02457199
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2025-09-29
Health Canada: Marketed since 2025-10-15 · brand TARO-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Taro pharmaceuticals inc · schedule Prescription
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94427 · Verify on the e-Formulary ↗ (DIN 02457199)
Source record
DIN 02457199: Taro-Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id TAR
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.4814; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02457199
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94427
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611
Accel-Duloxetine · DIN 02522861 · $0.3611
Apo-Duloxetine · DIN 02440423 · $0.3611
Auro-Duloxetine · DIN 02436647 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02453630 · $0.3611
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
Jamp-Duloxetine · DIN 02451913 · $0.3611
M-Duloxetine · DIN 02473208 · $0.3611
Mar-Duloxetine · DIN 02446081 · $0.3611
Mint-Duloxetine · DIN 02438984 · $0.3611
NRA-Duloxetine · DIN 02482126 · $0.3611
PMS-Duloxetine · DIN 02429446 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Sandoz Duloxetine · DIN 02439948 · $0.3611
Teva-Duloxetine · DIN 02456753 · $0.3611
Shortage status: active shortage (reported 2026-02-01, estimated to end 2026-09-11, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457199
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Duloxetine · DIN 02456753 · 30mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Duloxetine · DIN 02456753
Manufacturer: Teva Canada Limited; listing date 2020-06-30
Health Canada: Marketed since 2020-04-24 · brand TEVA-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 30 MG · company Teva canada limited · schedule Prescription
Ministry pays: $0.3611 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94374 · Verify on the e-Formulary ↗ (DIN 02456753)
Source record
DIN 02456753: Teva-Duloxetine
Raw flags: sec3=Y
Item: 281604123; group id 459; item number 1148; lccId None; manufacturer id TEV
Source form: DR Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $0.4814; ministry $0.3611
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456753
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94374
Interchangeable products
AG-Duloxetine · DIN 02475308 · $0.3611
Accel-Duloxetine · DIN 02522861 · $0.3611
Apo-Duloxetine · DIN 02440423 · $0.3611
Auro-Duloxetine · DIN 02436647 · $0.3611
Cymbalta · DIN 02301482 · not recorded
Duloxetine · DIN 02453630 · $0.3611
Duloxetine · DIN 02490889 · $0.3611
Duloxetine DR · DIN 02437082 · $0.3611
Jamp Duloxetine Capsules · DIN 02512505 · $0.3611
Jamp-Duloxetine · DIN 02451913 · $0.3611
M-Duloxetine · DIN 02473208 · $0.3611
Mar-Duloxetine · DIN 02446081 · $0.3611
Mint-Duloxetine · DIN 02438984 · $0.3611
NRA-Duloxetine · DIN 02482126 · $0.3611
PMS-Duloxetine · DIN 02429446 · $0.3611
Ran-Duloxetine · DIN 02438259 · $0.3611
Sandoz Duloxetine · DIN 02439948 · $0.3611
Taro-Duloxetine · DIN 02457199 · $0.3611
Shortage status: active shortage (reported 2026-06-24, estimated to end 2026-10-10, last updated 2026-06-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02456753
Shortage record checked 2026-09-13T08:10:21.292534+00:00
AG-Duloxetine · DIN 02475316 · 60mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Duloxetine · DIN 02475316
Manufacturer: Angita Pharma Inc.; listing date 2020-11-30
Health Canada: Marketed since 2018-07-19 · brand AG-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 60 MG · company Angita pharma inc. · schedule Prescription
Ministry pays: $0.7327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96568 · Verify on the e-Formulary ↗ (DIN 02475316)
Source record
DIN 02475316: AG-Duloxetine
Raw flags: sec3=Y
Item: 281604124; group id 459; item number 1149; lccId None; manufacturer id ANG
Source form: DR Cap; strength: 60mg
Recorded listing: General benefit
Source prices (unrounded): $0.9769; ministry $0.7327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475316
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96568
Interchangeable products
Accel-Duloxetine · DIN 02522888 · $0.7327
Apo-Duloxetine · DIN 02440431 · $0.7327
Auro-Duloxetine · DIN 02436655 · $0.7327
Cymbalta · DIN 02301490 · not recorded
Duloxetine · DIN 02453649 · $0.7327
Duloxetine · DIN 02490897 · $0.7327
Duloxetine DR · DIN 02437090 · $0.7327
Jamp Duloxetine Capsules · DIN 02512513 · $0.7327
Jamp-Duloxetine · DIN 02451921 · $0.7327
M-Duloxetine · DIN 02473216 · $0.7327
Mar-Duloxetine · DIN 02446103 · $0.7327
Mint-Duloxetine · DIN 02438992 · $0.7327
NRA-Duloxetine · DIN 02482134 · $0.7327
PMS-Duloxetine · DIN 02429454 · $0.7327
Ran-Duloxetine · DIN 02438267 · $0.7327
Sandoz Duloxetine · DIN 02439956 · $0.7327
Taro-Duloxetine · DIN 02457202 · $0.7327
Teva-Duloxetine · DIN 02456761 · $0.7327
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02475316
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Accel-Duloxetine · DIN 02522888 · 60mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Accel-Duloxetine · DIN 02522888
Manufacturer: Accel Pharma Inc.; listing date 2022-05-31
Health Canada: Marketed since 2022-04-04 · brand ACCEL-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 60 MG · company Accel pharma inc · schedule Prescription
Accel-Duloxetine: Formulary list price $0.7327/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.7327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101197 · Verify on the e-Formulary ↗ (DIN 02522888)
Source record
DIN 02522888: Accel-Duloxetine
Raw flags: sec3=Y
Item: 281604124; group id 459; item number 1149; lccId None; manufacturer id ACC
Source form: DR Cap; strength: 60mg
Recorded listing: General benefit
Source prices (unrounded): $0.7327; ministry $0.7327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522888
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101197
Interchangeable products
AG-Duloxetine · DIN 02475316 · $0.7327
Apo-Duloxetine · DIN 02440431 · $0.7327
Auro-Duloxetine · DIN 02436655 · $0.7327
Cymbalta · DIN 02301490 · not recorded
Duloxetine · DIN 02453649 · $0.7327
Duloxetine · DIN 02490897 · $0.7327
Duloxetine DR · DIN 02437090 · $0.7327
Jamp Duloxetine Capsules · DIN 02512513 · $0.7327
Jamp-Duloxetine · DIN 02451921 · $0.7327
M-Duloxetine · DIN 02473216 · $0.7327
Mar-Duloxetine · DIN 02446103 · $0.7327
Mint-Duloxetine · DIN 02438992 · $0.7327
NRA-Duloxetine · DIN 02482134 · $0.7327
PMS-Duloxetine · DIN 02429454 · $0.7327
Ran-Duloxetine · DIN 02438267 · $0.7327
Sandoz Duloxetine · DIN 02439956 · $0.7327
Taro-Duloxetine · DIN 02457202 · $0.7327
Teva-Duloxetine · DIN 02456761 · $0.7327
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02522888
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Duloxetine · DIN 02440431 · 60mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Duloxetine · DIN 02440431
Manufacturer: Apotex Inc.; listing date 2016-06-29
Health Canada: Marketed since 2016-05-03 · brand APO-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 60 MG · company Apotex inc · schedule Prescription
Ministry pays: $0.7327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92480 · Verify on the e-Formulary ↗ (DIN 02440431)
Source record
DIN 02440431: Apo-Duloxetine
Raw flags: sec3=Y
Item: 281604124; group id 459; item number 1149; lccId None; manufacturer id APX
Source form: DR Cap; strength: 60mg
Recorded listing: General benefit
Source prices (unrounded): $0.9769; ministry $0.7327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02440431
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92480
Interchangeable products
AG-Duloxetine · DIN 02475316 · $0.7327
Accel-Duloxetine · DIN 02522888 · $0.7327
Auro-Duloxetine · DIN 02436655 · $0.7327
Cymbalta · DIN 02301490 · not recorded
Duloxetine · DIN 02453649 · $0.7327
Duloxetine · DIN 02490897 · $0.7327
Duloxetine DR · DIN 02437090 · $0.7327
Jamp Duloxetine Capsules · DIN 02512513 · $0.7327
Jamp-Duloxetine · DIN 02451921 · $0.7327
M-Duloxetine · DIN 02473216 · $0.7327
Mar-Duloxetine · DIN 02446103 · $0.7327
Mint-Duloxetine · DIN 02438992 · $0.7327
NRA-Duloxetine · DIN 02482134 · $0.7327
PMS-Duloxetine · DIN 02429454 · $0.7327
Ran-Duloxetine · DIN 02438267 · $0.7327
Sandoz Duloxetine · DIN 02439956 · $0.7327
Taro-Duloxetine · DIN 02457202 · $0.7327
Teva-Duloxetine · DIN 02456761 · $0.7327
Shortage status: resolved shortage (ended 2026-06-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02440431
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Duloxetine · DIN 02436655 · 60mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Duloxetine · DIN 02436655
Manufacturer: Auro Pharma Inc.; listing date 2016-06-29
Health Canada: Marketed since 2016-05-02 · brand AURO-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 60 MG · company Auro pharma inc · schedule Prescription
Ministry pays: $0.7327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92098 · Verify on the e-Formulary ↗ (DIN 02436655)
Source record
DIN 02436655: Auro-Duloxetine
Raw flags: sec3=Y
Item: 281604124; group id 459; item number 1149; lccId None; manufacturer id AUR
Source form: DR Cap; strength: 60mg
Recorded listing: General benefit
Source prices (unrounded): $0.9769; ministry $0.7327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02436655
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92098
Interchangeable products
AG-Duloxetine · DIN 02475316 · $0.7327
Accel-Duloxetine · DIN 02522888 · $0.7327
Apo-Duloxetine · DIN 02440431 · $0.7327
Cymbalta · DIN 02301490 · not recorded
Duloxetine · DIN 02453649 · $0.7327
Duloxetine · DIN 02490897 · $0.7327
Duloxetine DR · DIN 02437090 · $0.7327
Jamp Duloxetine Capsules · DIN 02512513 · $0.7327
Jamp-Duloxetine · DIN 02451921 · $0.7327
M-Duloxetine · DIN 02473216 · $0.7327
Mar-Duloxetine · DIN 02446103 · $0.7327
Mint-Duloxetine · DIN 02438992 · $0.7327
NRA-Duloxetine · DIN 02482134 · $0.7327
PMS-Duloxetine · DIN 02429454 · $0.7327
Ran-Duloxetine · DIN 02438267 · $0.7327
Sandoz Duloxetine · DIN 02439956 · $0.7327
Taro-Duloxetine · DIN 02457202 · $0.7327
Teva-Duloxetine · DIN 02456761 · $0.7327
Shortage status: resolved shortage (ended 2024-07-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02436655
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Duloxetine · DIN 02453649 · 60mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Duloxetine · DIN 02453649
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2016-05-05 · brand DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 60 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Ministry pays: $0.7327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94020 · Verify on the e-Formulary ↗ (DIN 02453649)
Source record
DIN 02453649: Duloxetine
Raw flags: sec3=Y
Item: 281604124; group id 459; item number 1149; lccId None; manufacturer id SIV
Source form: DR Cap; strength: 60mg
Recorded listing: General benefit
Source prices (unrounded): $0.9769; ministry $0.7327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02453649
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94020
Interchangeable products
AG-Duloxetine · DIN 02475316 · $0.7327
Accel-Duloxetine · DIN 02522888 · $0.7327
Apo-Duloxetine · DIN 02440431 · $0.7327
Auro-Duloxetine · DIN 02436655 · $0.7327
Cymbalta · DIN 02301490 · not recorded
Duloxetine · DIN 02490897 · $0.7327
Duloxetine DR · DIN 02437090 · $0.7327
Jamp Duloxetine Capsules · DIN 02512513 · $0.7327
Jamp-Duloxetine · DIN 02451921 · $0.7327
M-Duloxetine · DIN 02473216 · $0.7327
Mar-Duloxetine · DIN 02446103 · $0.7327
Mint-Duloxetine · DIN 02438992 · $0.7327
NRA-Duloxetine · DIN 02482134 · $0.7327
PMS-Duloxetine · DIN 02429454 · $0.7327
Ran-Duloxetine · DIN 02438267 · $0.7327
Sandoz Duloxetine · DIN 02439956 · $0.7327
Taro-Duloxetine · DIN 02457202 · $0.7327
Teva-Duloxetine · DIN 02456761 · $0.7327
Shortage status: resolved shortage (ended 2024-10-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453649
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Duloxetine · DIN 02451921 · 60mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Duloxetine · DIN 02451921
Manufacturer: Jamp Pharma Corporation; listing date 2016-07-28
Health Canada: Marketed since 2016-05-03 · brand JAMP-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 60 MG · company Jamp pharma corporation · schedule Prescription
Ministry pays: $0.7327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93832 · Verify on the e-Formulary ↗ (DIN 02451921)
Source record
DIN 02451921: Jamp-Duloxetine
Raw flags: sec3=Y
Item: 281604124; group id 459; item number 1149; lccId None; manufacturer id JPC
Source form: DR Cap; strength: 60mg
Recorded listing: General benefit
Source prices (unrounded): $0.9769; ministry $0.7327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02451921
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93832
Interchangeable products
AG-Duloxetine · DIN 02475316 · $0.7327
Accel-Duloxetine · DIN 02522888 · $0.7327
Apo-Duloxetine · DIN 02440431 · $0.7327
Auro-Duloxetine · DIN 02436655 · $0.7327
Cymbalta · DIN 02301490 · not recorded
Duloxetine · DIN 02453649 · $0.7327
Duloxetine · DIN 02490897 · $0.7327
Duloxetine DR · DIN 02437090 · $0.7327
Jamp Duloxetine Capsules · DIN 02512513 · $0.7327
M-Duloxetine · DIN 02473216 · $0.7327
Mar-Duloxetine · DIN 02446103 · $0.7327
Mint-Duloxetine · DIN 02438992 · $0.7327
NRA-Duloxetine · DIN 02482134 · $0.7327
PMS-Duloxetine · DIN 02429454 · $0.7327
Ran-Duloxetine · DIN 02438267 · $0.7327
Sandoz Duloxetine · DIN 02439956 · $0.7327
Taro-Duloxetine · DIN 02457202 · $0.7327
Teva-Duloxetine · DIN 02456761 · $0.7327
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02451921
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Duloxetine · DIN 02473216 · 60mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Duloxetine · DIN 02473216
Manufacturer: Mantra Pharma Inc.; listing date 2021-11-30
Health Canada: Marketed since 2019-06-27 · brand M-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 60 MG · company Mantra pharma inc · schedule Prescription
Ministry pays: $0.7327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96255 · Verify on the e-Formulary ↗ (DIN 02473216)
Source record
DIN 02473216: M-Duloxetine
Raw flags: sec3=Y
Item: 281604124; group id 459; item number 1149; lccId None; manufacturer id MAT
Source form: DR Cap; strength: 60mg
Recorded listing: General benefit
Source prices (unrounded): $0.9769; ministry $0.7327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02473216
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96255
Interchangeable products
AG-Duloxetine · DIN 02475316 · $0.7327
Accel-Duloxetine · DIN 02522888 · $0.7327
Apo-Duloxetine · DIN 02440431 · $0.7327
Auro-Duloxetine · DIN 02436655 · $0.7327
Cymbalta · DIN 02301490 · not recorded
Duloxetine · DIN 02453649 · $0.7327
Duloxetine · DIN 02490897 · $0.7327
Duloxetine DR · DIN 02437090 · $0.7327
Jamp Duloxetine Capsules · DIN 02512513 · $0.7327
Jamp-Duloxetine · DIN 02451921 · $0.7327
Mar-Duloxetine · DIN 02446103 · $0.7327
Mint-Duloxetine · DIN 02438992 · $0.7327
NRA-Duloxetine · DIN 02482134 · $0.7327
PMS-Duloxetine · DIN 02429454 · $0.7327
Ran-Duloxetine · DIN 02438267 · $0.7327
Sandoz Duloxetine · DIN 02439956 · $0.7327
Taro-Duloxetine · DIN 02457202 · $0.7327
Teva-Duloxetine · DIN 02456761 · $0.7327
Shortage status: resolved shortage (ended 2025-11-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02473216
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Duloxetine · DIN 02446103 · 60mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Duloxetine · DIN 02446103
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2016-08-30
Health Canada: Marketed since 2019-05-14 · brand MAR-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 60 MG · company Marcan pharmaceuticals inc · schedule Prescription
Ministry pays: $0.7327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93137 · Verify on the e-Formulary ↗ (DIN 02446103)
Source record
DIN 02446103: Mar-Duloxetine
Raw flags: sec3=Y
Item: 281604124; group id 459; item number 1149; lccId None; manufacturer id MAR
Source form: DR Cap; strength: 60mg
Recorded listing: General benefit
Source prices (unrounded): $0.9769; ministry $0.7327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02446103
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93137
Interchangeable products
AG-Duloxetine · DIN 02475316 · $0.7327
Accel-Duloxetine · DIN 02522888 · $0.7327
Apo-Duloxetine · DIN 02440431 · $0.7327
Auro-Duloxetine · DIN 02436655 · $0.7327
Cymbalta · DIN 02301490 · not recorded
Duloxetine · DIN 02453649 · $0.7327
Duloxetine · DIN 02490897 · $0.7327
Duloxetine DR · DIN 02437090 · $0.7327
Jamp Duloxetine Capsules · DIN 02512513 · $0.7327
Jamp-Duloxetine · DIN 02451921 · $0.7327
M-Duloxetine · DIN 02473216 · $0.7327
Mint-Duloxetine · DIN 02438992 · $0.7327
NRA-Duloxetine · DIN 02482134 · $0.7327
PMS-Duloxetine · DIN 02429454 · $0.7327
Ran-Duloxetine · DIN 02438267 · $0.7327
Sandoz Duloxetine · DIN 02439956 · $0.7327
Taro-Duloxetine · DIN 02457202 · $0.7327
Teva-Duloxetine · DIN 02456761 · $0.7327
Shortage status: resolved shortage (ended 2019-05-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02446103
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Duloxetine · DIN 02438992 · 60mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Duloxetine · DIN 02438992
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2016-06-29
Health Canada: Marketed since 2016-05-02 · brand MINT-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 60 MG · company Mint pharmaceuticals inc · schedule Prescription
Ministry pays: $0.7327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92336 · Verify on the e-Formulary ↗ (DIN 02438992)
Source record
DIN 02438992: Mint-Duloxetine
Raw flags: sec3=Y
Item: 281604124; group id 459; item number 1149; lccId None; manufacturer id MIN
Source form: DR Cap; strength: 60mg
Recorded listing: General benefit
Source prices (unrounded): $0.9769; ministry $0.7327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02438992
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92336
Interchangeable products
AG-Duloxetine · DIN 02475316 · $0.7327
Accel-Duloxetine · DIN 02522888 · $0.7327
Apo-Duloxetine · DIN 02440431 · $0.7327
Auro-Duloxetine · DIN 02436655 · $0.7327
Cymbalta · DIN 02301490 · not recorded
Duloxetine · DIN 02453649 · $0.7327
Duloxetine · DIN 02490897 · $0.7327
Duloxetine DR · DIN 02437090 · $0.7327
Jamp Duloxetine Capsules · DIN 02512513 · $0.7327
Jamp-Duloxetine · DIN 02451921 · $0.7327
M-Duloxetine · DIN 02473216 · $0.7327
Mar-Duloxetine · DIN 02446103 · $0.7327
NRA-Duloxetine · DIN 02482134 · $0.7327
PMS-Duloxetine · DIN 02429454 · $0.7327
Ran-Duloxetine · DIN 02438267 · $0.7327
Sandoz Duloxetine · DIN 02439956 · $0.7327
Taro-Duloxetine · DIN 02457202 · $0.7327
Teva-Duloxetine · DIN 02456761 · $0.7327
Shortage status: resolved shortage (ended 2018-05-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02438992
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Duloxetine · DIN 02482134 · 60mg · DR capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Duloxetine · DIN 02482134
Manufacturer: Nora Pharma; listing date 2020-07-31
Health Canada: Marketed since 2019-03-06 · brand NRA-DULOXETINE · ATC N06AX21 DULOXETINE · form Capsule (delayed-release) · route Oral · ingredients DULOXETINE (DULOXETINE HYDROCHLORIDE) 60 MG · company Nora pharma inc · schedule Prescription
Ministry pays: $0.7327 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97244 · Verify on the e-Formulary ↗ (DIN 02482134)
Source record
DIN 02482134: NRA-Duloxetine
Raw flags: sec3=Y
Item: 281604124; group id 459; item number 1149; lccId None; manufacturer id NRA
Source form: DR Cap; strength: 60mg
Recorded listing: General benefit
Source prices (unrounded): $0.9769; ministry $0.7327
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02482134
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97244
Interchangeable products
AG-Duloxetine · DIN 02475316 · $0.7327
Accel-Duloxetine · DIN 02522888 · $0.7327
Apo-Duloxetine · DIN 02440431 · $0.7327
Auro-Duloxetine · DIN 02436655 · $0.7327
Cymbalta · DIN 02301490 · not recorded
Duloxetine · DIN 02453649 · $0.7327
Duloxetine · DIN 02490897 · $0.7327
Duloxetine DR · DIN 02437090 · $0.7327
Jamp Duloxetine Capsules · DIN 02512513 · $0.7327
Jamp-Duloxetine · DIN 02451921 · $0.7327
M-Duloxetine · DIN 02473216 · $0.7327
Mar-Duloxetine · DIN 02446103 · $0.7327
Mint-Duloxetine · DIN 02438992 · $0.7327
PMS-Duloxetine · DIN 02429454 · $0.7327
Ran-Duloxetine · DIN 02438267 · $0.7327
Sandoz Duloxetine · DIN 02439956 · $0.7327
Taro-Duloxetine · DIN 02457202 · $0.7327
Teva-Duloxetine · DIN 02456761 · $0.7327
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02482134
Shortage record checked 2026-09-13T08:10:21.292534+00:00